Breast lumps classification: Difference between revisions

Jump to navigation Jump to search
m (Bot: Removing from Primary care)
 
(8 intermediate revisions by 2 users not shown)
Line 6: Line 6:




[[Breast lumps]] may be classified according to [[epithelial]] [[hyperplasia]] into 3 subtypes: non-proliferative, proliferative disease and proliferative disease without [[atypia]].
[[Breast lumps]] may be classified according to [[epithelial]] [[hyperplasia]] into 3 subtypes: non-proliferative, proliferative disease and proliferative disease without [[atypia]]. [[Breast lumps]] may be classified into 3 sub-types based on [[histological]] regions: [[lobular]] region, ductal region, different origins.
 
[[Breast lumps]] may be classified into 3 subtypes based on [[histological]] regions: [[lobular]] region, ductal region, different origins.


==Classification==
==Classification==


'''Classification of [[breast lumps]] based on [[epithelial hyperplasia]]<ref name="pmid16034008">{{cite journal| author=Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K et al.| title=Benign breast disease and the risk of breast cancer. | journal=N Engl J Med | year= 2005 | volume= 353 | issue= 3 | pages= 229-37 | pmid=16034008 | doi=10.1056/NEJMoa044383 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16034008  }} </ref>'''<ref name="pmid1734106">{{cite journal| author=London SJ, Connolly JL, Schnitt SJ, Colditz GA| title=A prospective study of benign breast disease and the risk of breast cancer. | journal=JAMA | year= 1992 | volume= 267 | issue= 7 | pages= 941-4 | pmid=1734106 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1734106  }}</ref>
'''Classification of breast lumps based on epithelial hyperplasia:'''<ref name="pmid16034008">{{cite journal| author=Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K et al.| title=Benign breast disease and the risk of breast cancer. | journal=N Engl J Med | year= 2005 | volume= 353 | issue= 3 | pages= 229-37 | pmid=16034008 | doi=10.1056/NEJMoa044383 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16034008  }} </ref><ref name="pmid1734106">{{cite journal| author=London SJ, Connolly JL, Schnitt SJ, Colditz GA| title=A prospective study of benign breast disease and the risk of breast cancer. | journal=JAMA | year= 1992 | volume= 267 | issue= 7 | pages= 941-4 | pmid=1734106 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1734106 }}</ref><ref name="pmid39659322">{{cite journal| author=Dupont WD, Page DL| title=Risk factors for breast cancer in women with proliferative breast disease. | journal=N Engl J Med | year= 1985 | volume= 312 | issue= 3 | pages= 146-51 | pmid=3965932 | doi=10.1056/NEJM198501173120303 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3965932 }}</ref>
*Approximately 65% of all benign breast disease considered as [[nonproliferative|non-proliferative]] (NP) with relative cancer risk of 1.2, 1.4 times:
*Approximately 65% of all benign breast disease considered as non-proliferative (NP) with relative cancer risk of 1.2 - 1.4 times:
**[[Cyst]]
**[[Cyst]] (most common)<ref name="pmid7110289">{{cite journal| author=Love SM, Gelman RS, Silen W| title=Sounding board. Fibrocystic "disease" of the breast--a nondisease? | journal=N Engl J Med | year= 1982 | volume= 307 | issue= 16 | pages= 1010-4 | pmid=7110289 | doi=10.1056/NEJM198210143071611 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7110289  }} </ref>
***The most common type in non- proliferative category<ref name="pmid7110289">{{cite journal| author=Love SM, Gelman RS, Silen W| title=Sounding board. Fibrocystic "disease" of the breast--a nondisease? | journal=N Engl J Med | year= 1982 | volume= 307 | issue= 16 | pages= 1010-4 | pmid=7110289 | doi=10.1056/NEJM198210143071611 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7110289  }} </ref>
**[[Fibrosis]]
**[[Fibrosis]]
** [[Fibroadenoma]] (simple)
** [[Fibroadenoma]] (simple)
Line 21: Line 18:
** [[Apocrine]] [[metaplasia]] (simple)
** [[Apocrine]] [[metaplasia]] (simple)
** Mild ductal [[hyperplasia]]  
** Mild ductal [[hyperplasia]]  
* Approximately 30% of total are classified as (PD) with relative cancer risk of 1.7, 2.1 times<ref name="pmid3965932">{{cite journal| author=Dupont WD, Page DL| title=Risk factors for breast cancer in women with proliferative breast disease. | journal=N Engl J Med | year= 1985 | volume= 312 | issue= 3 | pages= 146-51 | pmid=3965932 | doi=10.1056/NEJM198501173120303 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3965932  }}</ref>
* Approximately 30% of total are classified as proliferative disease (PD) with relative cancer risk of 1.7 - 2.1 times:<ref name="pmid3965932">{{cite journal| author=Dupont WD, Page DL| title=Risk factors for breast cancer in women with proliferative breast disease. | journal=N Engl J Med | year= 1985 | volume= 312 | issue= 3 | pages= 146-51 | pmid=3965932 | doi=10.1056/NEJM198501173120303 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3965932  }}</ref>
** Usual ductal [[hyperplasia]]
** Usual ductal [[hyperplasia]]
**  Sclerosing adenosis
**  [[Sclerosing adenosis]]
** Columnar [[hyperplasia]]  
** Columnar [[hyperplasia]]  
** [[papilloma]]
** [[Papilloma]]
** Radical scar
** Radical scar
* Approximately 5% to 8% of the rest regarded to PD with [[atypia]] and relative cancer risk more than 4 times<ref name="pmid6275978">{{cite journal| author=Page DL, Dupont WD, Rogers LW, Landenberger M| title=Intraductal carcinoma of the breast: follow-up after biopsy only. | journal=Cancer | year= 1982 | volume= 49 | issue= 4 | pages= 751-8 | pmid=6275978 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=6275978  }}</ref>
* Approximately 5% to 8% of the rest are regarded as PD with [[atypia]] and relative cancer risk more than 4 times:<ref name="pmid6275978">{{cite journal| author=Page DL, Dupont WD, Rogers LW, Landenberger M| title=Intraductal carcinoma of the breast: follow-up after biopsy only. | journal=Cancer | year= 1982 | volume= 49 | issue= 4 | pages= 751-8 | pmid=6275978 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=6275978  }}</ref>
** Atypical lobar [[hyperplasia]]
** Atypical lobar [[hyperplasia]]
** [[Lobular]] [[carcinoma]] [[in situ]]
** [[Lobular]] [[carcinoma]] [[in situ]]
Line 35: Line 32:
** [[Apocrine]] [[atypia]]
** [[Apocrine]] [[atypia]]
** Secretory [[atypia]]
** Secretory [[atypia]]
'''Classification of [[benign breast lesion]] regarding to [[histological region|histologist region]]''':<ref>{{cite book | last = Lanyi | first = M | title = Mammography : diagnosis and pathological analysis | publisher = Springer-Verlag | location = Berlin New York | year = 2003 | isbn = 9783540441137 }}</ref>
'''Classification of [[benign breast lesion]] according to histological region''':<ref>{{cite book | last = Lanyi | first = M | title = Mammography : diagnosis and pathological analysis | publisher = Springer-Verlag | location = Berlin New York | year = 2003 | isbn = 9783540441137 }}</ref>
*Terminal and [[lobular]] ducts
*Terminal and [[lobular]] ducts
**[[Acinar]] distention  
**[[Acinar]] distention  
***[[Cyst]]
***[[Cyst]]
**Intralobular connective tissue proliferation
**Intralobular connective tissue proliferation
***Sclerosing adenosis
***[[Sclerosing adenosis]]
***[[Fibroadenoma]]
***[[Fibroadenoma]]
***[[Phyllodes tumor]]
***[[Phyllodes tumor]]
***[[Hamartoma]]
***[[Hamartoma]]
**Epithelial changes in terminal duct [[lobular]] units (TDLU)
**[[Epithelial]] changes in terminal duct [[lobular]] units (TDLU)
***[[Apocrine]] [[metaplasia]]
***[[Apocrine]] [[metaplasia]]
***Ductal and [[lobular]] [[hyperplasia]], usual and typical
***Ductal and [[lobular]] [[hyperplasia]], usual and typical
Line 58: Line 55:
**[[Fibrous]] tissue lesions
**[[Fibrous]] tissue lesions
***Focal [[fibrosis]]
***Focal [[fibrosis]]
***[[Diabetic]] mastopathy
***[[Diabetic]] mastopathy or lymphocytic mastitis or lymphocytic mastopathy<ref name="pmid16297091">{{cite journal| author=Lai EC, Chan WC, Ma TK, Tang AP, Poon CS, Leong HT| title=The role of conservative treatment in idiopathic granulomatous mastitis. | journal=Breast J | year= 2005 | volume= 11 | issue= 6 | pages= 454-6 | pmid=16297091 | doi=10.1111/j.1075-122X.2005.00127.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16297091  }}</ref><ref name="pmid11772912">{{cite journal| author=Kudva YC, Reynolds C, O'Brien T, Powell C, Oberg AL, Crotty TB| title="Diabetic mastopathy," or sclerosing lymphocytic lobulitis, is strongly associated with type 1 diabetes. | journal=Diabetes Care | year= 2002 | volume= 25 | issue= 1 | pages= 121-6 | pmid=11772912 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11772912  }}</ref>
***Pseudoangiomatous [[stromal]] [[hyperplasia]] (PASH)
***Pseudoangiomatous [[stromal]] [[hyperplasia]] (PASH)
***Myofibroblastoma
***Myofibroblastoma
Line 72: Line 69:
==References==
==References==
{{Reflist|2}}
{{Reflist|2}}
{{WH}}
 
{{WS}}
 
[[Category: (name of the system)]]
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
 
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Gynecology]]
[[Category:Surgery]]

Latest revision as of 20:42, 29 July 2020

Breast lumps Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Breast lumps from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Breast lumps classification On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Breast lumps classification

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Breast lumps classification

on Breast lumps classification

Breast lumps classification in the news

Blogs on Breast lumps classification

Directions to Hospitals Treating Breast lumps

Risk calculators and risk factors for Breast lumps classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shadan Mehraban, M.D.[2]

Overview

Breast lumps may be classified according to epithelial hyperplasia into 3 subtypes: non-proliferative, proliferative disease and proliferative disease without atypia. Breast lumps may be classified into 3 sub-types based on histological regions: lobular region, ductal region, different origins.

Classification

Classification of breast lumps based on epithelial hyperplasia:[1][2][3]

Classification of benign breast lesion according to histological region:[7]

References

  1. Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K; et al. (2005). "Benign breast disease and the risk of breast cancer". N Engl J Med. 353 (3): 229–37. doi:10.1056/NEJMoa044383. PMID 16034008.
  2. London SJ, Connolly JL, Schnitt SJ, Colditz GA (1992). "A prospective study of benign breast disease and the risk of breast cancer". JAMA. 267 (7): 941–4. PMID 1734106.
  3. Dupont WD, Page DL (1985). "Risk factors for breast cancer in women with proliferative breast disease". N Engl J Med. 312 (3): 146–51. doi:10.1056/NEJM198501173120303. PMID 3965932.
  4. Love SM, Gelman RS, Silen W (1982). "Sounding board. Fibrocystic "disease" of the breast--a nondisease?". N Engl J Med. 307 (16): 1010–4. doi:10.1056/NEJM198210143071611. PMID 7110289.
  5. Dupont WD, Page DL (1985). "Risk factors for breast cancer in women with proliferative breast disease". N Engl J Med. 312 (3): 146–51. doi:10.1056/NEJM198501173120303. PMID 3965932.
  6. Page DL, Dupont WD, Rogers LW, Landenberger M (1982). "Intraductal carcinoma of the breast: follow-up after biopsy only". Cancer. 49 (4): 751–8. PMID 6275978.
  7. Lanyi, M (2003). Mammography : diagnosis and pathological analysis. Berlin New York: Springer-Verlag. ISBN 9783540441137.
  8. Lai EC, Chan WC, Ma TK, Tang AP, Poon CS, Leong HT (2005). "The role of conservative treatment in idiopathic granulomatous mastitis". Breast J. 11 (6): 454–6. doi:10.1111/j.1075-122X.2005.00127.x. PMID 16297091.
  9. Kudva YC, Reynolds C, O'Brien T, Powell C, Oberg AL, Crotty TB (2002). ""Diabetic mastopathy," or sclerosing lymphocytic lobulitis, is strongly associated with type 1 diabetes". Diabetes Care. 25 (1): 121–6. PMID 11772912.


Template:WikiDoc Sources